Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target on shares of ThermoGenesisHoldingsInc . in a report on Thursday, November 21st.
THMO stock traded up $0.10 during midday trading on Tuesday, reaching $4.80. 664 shares of the company’s stock traded hands, compared to its average volume of 87,724. The business has a 50-day moving average of $3.45. ThermoGenesisHoldingsInc . has a 1-year low of $2.35 and a 1-year high of $7.00. The stock has a market cap of $12.58 million, a P/E ratio of -1.34 and a beta of 1.02. The company has a current ratio of 1.96, a quick ratio of 1.36 and a debt-to-equity ratio of 1.16.
ThermoGenesisHoldingsInc . Company Profile
ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables.
Featured Article: How to Invest in an Index Fund
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ThermoGenesisHoldingsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesisHoldingsInc . and related companies with MarketBeat.com's FREE daily email newsletter.